Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated With Guselkumab: Posthoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Christopher Ritchlin,Philip Mease,Wolf-Henning Boehncke,John Tesser, Hugues Allard-Chamard,Soumya Chakravarty,Emmanouil Rampakakis,May Shawi, Elena Schiopu,Joseph Merola,Iain McInnes,Atul Deodhar

ARTHRITIS & RHEUMATOLOGY（2023）

引用 0|浏览7

暂无评分

摘要

Background: Introduction: The objective of this post-hoc analysis was to evaluate the efficacy of guselkumab (GUS) in inducing long-term (Week [W]100) stringent disease control in GRAPPA- recommended domains across patient subgroups defined by varying baseline characteristics.

查看译文

关键词

psoriatic arthritis domains,guselkumab,stringent disease activity control,post-hoc,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要